Skip to Main Content

Paper Details

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Circulation
29
2022
Acute Coronary Syndrome, Alirocumab, Apolipoprotein B, MACE, acute coronary syndrome, alirocumab, apoB, cholesterol, coronary heart disease, fatal/nonfatal, high-density lipoprotein cholesterol, ischemic stroke, low-density lipoprotein cholesterol, non-, nonfatal myocardial infarction, patient, patients, statin, subtilisin/kexin type 9, unstable angina
Author NameAffiliation
Deepak L BhattBrigham and Women's Hospital Heart & Vascular Center and Harvard Medical School
Robert A HarringtonStanford Center for Clinical Research, Stanford University
  • 1 - 2

Datasets

Release 1.2